Callao, Peru Clinical Trials

A listing of Callao, Peru clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 100 clinical trials
A Phase 3 Efficacy Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer

A study of zolbetuximab (IMAB362) plus mFOLFOX6 versus placebo plus mFOLFOX6 in subjects with Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Why is this study being done? SPOTLIGHT is a new clinical study for adult patients who have any of: advanced unresectable gastric …

Site PE51006
 (5.6 away) Contact site
  • 485 views
  • 16 Sep, 2021
  • +239 other locations
Evaluating Newly Approved Drugs for Multidrug-resistant TB

endTB Clinical Trial a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of five new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB).

linezolid
delamanid
moxifloxacin
pyrazinamide
bedaquiline
Socios En Salud
 (5.6 away) Contact site
  • 223 views
  • 15 Sep, 2021
  • +7 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is either persistent or recurrent following adequate BCG induction (Cohort A), or that is nave to BCG treatment (Cohort B). The primary hypothesis …

Hospital Militar Central [Lima, Peru] ( Site 0604)
 (5.4 away) Contact site
  • 108 views
  • 16 Sep, 2021
  • +141 other locations
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Primary Objective: To evaluate the anti-leukemic activity of isatuximab in combination with standard chemotherapies in pediatric participants of ages 28 days to less than 18 years with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML) Secondary Objectives: Safety and tolerability assessments Assessment of infusion reactions (IRs) Pharmacokinetics (PK) …

minimal residual disease
doxorubicin
asparaginase
lymphoma
lymphoblastic lymphoma
Investigational Site Number 6040002
 (5.6 away) Contact site
  • 14 views
  • 14 Jun, 2021
  • +70 other locations
To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

Summit is developing ridinilazole as a novel antimicrobial for Clostridium difficile Infection (CDI), formerly known as Clostridium difficile Infection, with the goal of achieving comparable cure rates to standard of care, but reducing rates of recurrent disease. A phase 2 proof of concept study, with vancomycin as comparator, demonstrated these …

diarrhea
clostridium difficile
antibiotic therapy
ridinilazole
vancomycin
Hospital Nacional Alberto Sabogal Sologuren
 (1.4 away) Contact site
  • 18 views
  • 18 Apr, 2021
  • +181 other locations
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)

breast cancer
measurable disease
formalin-fixed paraffin-embedded
cancer
paclitaxel
Research Site
 (6.9 away) Contact site
  • 1387 views
  • 26 Aug, 2021
  • +309 other locations
Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary Fibrosis

This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in subjects with Idiopathic Pulmonary Fibrosis

nintedanib
idiopathic pulmonary fibrosis
pamrevlumab
carbon monoxide
diffusion capacity of the lung for carbon monoxide
Clinica Providencia
 (2.8 away) Contact site
  • 349 views
  • 16 Sep, 2021
  • +227 other locations
A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

Study MO39874 is an open-label, phase IIIb, single arm, multicenter study conducted in participants with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not received chemotherapy for their unresectable locally advanced or metastatic disease.

metastasis
adenocarcinoma
programmed cell death 1 ligand 1
atezolizumab
serum pregnancy test
Hospital Central Fap Juan Benavides Dorich; Oncology
 (3.9 away) Contact site
  • 147 views
  • 15 Sep, 2021
  • +163 other locations
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.

pemetrexed
gemcitabine
carboplatin
cancer chemotherapy
durvalumab
Research Site
 (1.3 away) Contact site
  • 251 views
  • 02 Sep, 2021
  • +320 other locations
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199) With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.

chemoimmunotherapy
bendamustine
rituximab
acalabrutinib
fludarabine
Research Site
 (8.0 away) Contact site
  • 342 views
  • 16 Sep, 2021
  • +245 other locations